Abbott v. SiBio – Glucose-Monitoring Device Patent Injunction (UPC)

This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →

## Overview Abbott has secured another preliminary injunction against SiBio over glucose-monitoring device (CGM) patents at the Unified Patent Court (UPC), continuing a pattern of aggressive patent enforcement in the medical device space (JUVE Patent, September 11, 2026). ## Key Details - The UPC's Milan local division, under presiding judge Pierluigi Perrotti, granted Abbott a preliminary injunction (case ID: UPC CFI no. 1086/2026) (JUVE Patent, September 11, 2026). - As a result, SiBio may no longer offer its glucose-monitoring system GS3-R or its components, or import or store the product within UPC jurisdiction (JUVE Patent, September 11, 2026). - SiBio must also disclose to Abbott the full [scope of its distribution network], per the injunction terms (JUVE Patent, September 11, 2026). ## Strategic Significance This is part of an ongoing pattern of Abbott using the UPC to enforce patent rights against competitors in the continuous glucose monitoring (CGM) market, a fast-growing medical device segment. The case adds to a broader trend of medical device preliminary injunctions being granted swiftly under the UPC framework, reinforcing the court's growing importance as a venue for pharma/medtech patent enforcement in Europe. ## Watch For - SiBio's appeal or response strategy. - Additional Abbott patent enforcement actions against other CGM competitors. - Broader UPC jurisprudence trends on preliminary injunctions in medical devices.